A Phase 2 interventional study of Sotatercept and Placebo in Chemotherapy Induced Anemia, sponsored by Merck Sharp & Dohme LLC. Terminated at 39 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 464 studies in Anemia with a site in United States — 38 open to participants now, 58 under way, 18 of them phase 3. Anemia · United States.
Among the 464 studies in Anemia with a site in United States, this one is the 267th largest by enrollment of the 395 interventional ones that give a count, is one of 13 that started in 2009, is one of 109 in phase 2, and was the 155th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →38 of the 464 studies in Anemia with a site in United States are open now. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
464 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 71 · Phase 2 136 · Phase 3 122 · Phase 4 34
First in 1992; this study’s year is marked. 13 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 72 across the 395 interventional studies, 116 across the 50 observational. Of the 367 that completed or were terminated, 196 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
231 of 464 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 7 studies filed under Anemia — fewer than ten, so there is no comparison to draw.
10 of the studies in Anemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06527391Phase 3University of MinnesotaCholine and Iron Deficiency | 2027-09-21 |
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT06106269Mayo ClinicOutcomes and Quality of Life Following Rectal Artery Embolization for Bleeding Internal Hemorrhoids | 2026-12 |
| NCT05340465University of WashingtonDarbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants | 2027-01-30 |
| NCT06788691Weill Medical College of Cornell UniversityLuspatercept for Clonal Cytopenias of Uncertain Significance | 2027-02 |
Add all 10 to your calendar (.ics) → With an account.
Among the 464 studies in Anemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the percentage of participants in each sotatercept dose regimen who achieve a hematopoietic response during the treatment period including up to 2 months after the last dose of sotatercept treatment of chemotherapy-induced anemia (CIA) in participants with metastatic breast cancer. Hematopoietic response was defined as an increase in hemoglobin concentration of ≥ 1 g/dL relative to baseline for 28 consecutive days during the treatment period including up to 2 months after the last dose of sotatercept in the absence of red blood cell (RBC) transfusion or treatment with an erythropoiesis-stimulating agent (ESA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive sotatercept 0.1 mg/kg subcutaneously every 28 days up to 4 doses.
Biological: Sotatercept
Participants will receive sotatercept 0.3 mg/kg subcutaneously every 28 days up to 4 doses.
Biological: Sotatercept
Participants will receive sotatercept 0.5 mg/kg subcutaneously every 28 days up to 4 doses.
Biological: Sotatercept
Participants will receive placebo subcutaneously every 28 days up to 4 doses.
Drug: Placebo
up to 4 subcutaneous doses of sotatercept given once every 28 days
Also known as: ACE-011
up to 4 subcutaneous doses of placebo given once every 28 days
Percentage of Participants Who Achieved a Hematopoietic Response
Hematopoietic response rate is defined as the percentage of participants who had increase in hemoglobin concentration of ≥ 1 g/dL relative to baseline for 28 consecutive days during the treatment period including up to 2 months after the last dose of study treatment in the absence of red blood cell (RBC) transfusion or treatment with an erythropoiesis-stimulating agent (ESA). The percentage of participants who achieved hematopoietic response is presented.
Time frame: Baseline and Up to ~145 Days
Number of Participants Who Experienced an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced AEs is reported.
Time frame: Up to ~175 Days
Number of Participants Who Discontinued Study Intervention Due to an Adverse Event
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study intervention due to AEs is reported.
Time frame: Up to ~85 Days
Percentage of Participants Achieving an Increase From Baseline Hemoglobin of ≥ 2 g/dL
Percentage of participants achieving an increase from baseline hemoglobin of ≥ 2 g/dL for 28 consecutive days during the treatment period and up to 2 months after the last dose of study treatment in the absence of RBC transfusion or treatment with an ESA. The percentage of participants achieving an increase from baseline hemoglobin of ≥ 2 g/dL for 28 consecutive days is presented.
Time frame: Baseline and Up to ~145 Days
Percentage of Participants Achieving an Increase From Baseline Hemoglobin ≥ 11 g/dL
Percentage of participants achieving hemoglobin ≥ 11 g/dL for 28 consecutive days during the treatment period and up to 2 months after the last dose of study treatment in the absence of RBC transfusion or treatment with an ESA. The percentage of participants achieving an increase from baseline hemoglobin of ≥ 11 g/dL for 28 consecutive days is presented.
Time frame: Baseline and Up to ~145 Days
Percentage of Participants Achieving an Increase From Baseline Hemoglobin of ≥2 g/dL and/or Hemoglobin ≥ 11 g/dL
Percentage of participants achieving an increase from baseline hemoglobin of ≥ 2 g/dL and/or hemoglobin ≥ 11 g/dL for 28 consecutive days during the treatment period and up to 2 months after the last dose of study treatment in the absence of RBC transfusion or treatment with an ESA. The percentage of participants achieving an increase from baseline hemoglobin of ≥ 2 g/dL and/or hemoglobin ≥ 11 g/dL for 28 consecutive days is presented.
Time frame: Baseline and Up to ~145 Days
Duration of Hematopoietic Response for Hemoglobin ≥ 1 g/dL
Duration of hematopoietic response is defined as the time period from the first time hemoglobin increases at least ≥ 1 g/dL from baseline to the last time there is hemoglobin ≥ 1 g/dL increase from baseline. Duration of response is only calculated for a responder and will be at least 28 days. The duration of response is only calculated for a patient who meets the primary efficacy endpoint. The data for duration of response for ≥ 1 g/dL from baseline is presented.
Time frame: Baseline and Up to ~145 Days
Duration of Hematopoietic Response for Hemoglobin ≥ 2 g/dL
Duration of hematopoietic response is defined as the time period from the first time hemoglobin increases at least ≥ 2 g/dL from baseline to the last time there is hemoglobin ≥ 2 g/dL increase from baseline. Duration of response is only calculated for a responder and will be at least 28 days. The duration of response is only calculated for a patient who meets the primary efficacy endpoint. The data for duration of response for hemoglobin ≥ 2 g/dL from baseline is presented.
Time frame: Baseline and Up to ~145 Days
Duration of Hematopoietic Response for Hemoglobin ≥ 11 g/dL
Duration of hematopoietic response is defined as the time period from the first time hemoglobin increases at least ≥ 11 g/dL from baseline to the last time there is hemoglobin ≥ 11 g/dL increase from baseline. Duration of response is only calculated for a responder and will be at least 28 days. The duration of response is only calculated for a patient who meets the primary efficacy endpoint. The data for duration of response for hemoglobin ≥ 11 g/dL from baseline is presented.
Time frame: Baseline and Up to ~145 Days
Duration of Hematopoietic Response for Hemoglobin Increases ≥ 1 g/dL and/or Hemoglobin Concentration ≥ 11 g/dL
Duration of hematopoietic response is defined as the time period the first time hemoglobin increases ≥ 1 g/dL and/or hemoglobin concentration is ≥ 11 g/dL from baseline to the last time when the same response is maintained. The data for duration of response for hemoglobin ≥ 1 g/dL and/or hemoglobin concentration ≥ 11 g/dL from baseline is presented.
Time frame: Baseline and Up to ~145 Days
Duration of Hematopoietic Response for Hemoglobin Increases ≥ 2 g/dL, and/or Hemoglobin Concentration ≥ 11 g/dL
Duration of hematopoietic response is defined as the time period the first time hemoglobin increases ≥ 2 g/dL, and/or hemoglobin concentration is ≥ 11 g/dL from baseline to the last time when the same response is maintained. The data for duration of response for hemoglobin ≥ 2 g/dL and/or hemoglobin concentration ≥ 11 g/dL from baseline is presented.
Time frame: Baseline and Up to ~145 Days
Time to Achieve Hematopoietic Response of Hemoglobin ≥ 1 g/dL Increase From Baseline
Time to achieve hematopoietic response based on ≥ 1 g/dL increase from baseline, is defined as the time from first dose of study treatment to the first hemoglobin increase ≥ 1 g/dL that was maintained for at least 28 consecutive days. The data for time to achieve hematopoietic response for hemoglobin ≥ 1 g/dL from baseline is presented.
Time frame: Baseline and Up to ~145 Days
Time to Achieve Hematopoietic Response of Hemoglobin ≥ 2 g/dL Increase From Baseline
Time to achieve hematopoietic response based on ≥ 2 g/dL increase from baseline, is defined as the time from first dose of study treatment to the first hemoglobin increase ≥ 2 g/dL that was maintained for at least 28 consecutive days. The data for duration of response for hemoglobin ≥ 2 g/dL from baseline is presented.
Time frame: Baseline and Up to ~145 Days
Time to Achieve Hematopoietic Response of Hemoglobin ≥ 11 g/dL From Baseline
Time to achieve hematopoietic response based on hemoglobin ≥ 11 g/dL, defined as the time from first dose of study treatment to the first hemoglobin ≥ 11 g/dL that was maintained for at least 28 consecutive days. The data for duration of response for hemoglobin ≥ 11 g/dL from baseline is presented.
Time frame: Baseline and Up to ~145 Days
Time to Achieve Hematopoietic Response of First Hemoglobin Increase ≥ 1 g/dL and/or Hemoglobin ≥ 11 g/dL
Time to achieve hematopoietic response based on multiple criteria categories, defined as the time from first dose of study treatment to first hemoglobin increase ≥ 1 g/dL and/or hemoglobin ≥ 11 g/dL that was maintained for at least 28 consecutive days. The data for duration of response for hemoglobin increase from baseline ≥ 1 g/dL and/or ≥ 11 g/dL from baseline is presented.
Time frame: Baseline and Up to ~145 Days
Time to Achieve Hematopoietic Response of First Hemoglobin Increase ≥ 2 g/dL and/or Hemoglobin ≥ 11 g/dL
Time to achieve hematopoietic response, defined as the time from first dose of study treatment to first hemoglobin increase ≥ 2 g/dL and/or hemoglobin ≥ 11 g/dL that was maintained for at least 28 consecutive days. The data for duration of response for hemoglobin increase from baseline ≥ 2 g/dL and/or ≥ 11 g/dL from baseline is presented.
Time frame: Baseline and Up to ~145 Days
Percentage of Participants Who Received RBC Transfusion or Treatment With an ESA
The percentage of participants who received RBC transfusion or treatment with an ESA in each study treatment group as well as within each cycle of each study treatment is presented.
Time frame: Up to Day 141
Objective Response Rate (ORR) for Target Lesions at Day 64 Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1).
ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR at Day 64 is presented.
Time frame: Baseline and Day 64
Objective Tumor Response Rate for Non-target Lesions at Day 64 Using RECIST v 1.1.
ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR of non-target lesions at Day 64 is presented.
Time frame: Day 64
Objective Tumor Response Rate for Target Lesions on Day 113 Using RECIST v 1.1.
ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR at Day 113 is presented.
Time frame: Day 113
Objective Tumor Response Rate for Non-target Lesions on Day 113 Using RECIST v 1.1.
ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR of non-target lesions at Day 113 is presented.
Time frame: Day 113
Progression-free Survival (PFS)
PFS was defined as the time from start of the chemotherapy regimen (which could have occurred prior to study start and collected as prior anticancer therapy) to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS per RECIST 1.1 is presented.
Time frame: From start of chemotherapy (which could have occurred prior to study start) up to Study Day 281
This study was terminated early after 30 participants were enrolled due to slower than expected rate of enrollment as a result of changes in guidance for the treatment of participants with breast cancer and chemotherapy induced anemia (CIA).
| Milestone | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Started | 8 | 10 | 7 | 5 |
| Completed | 3 | 1 | 1 | 2 |
| Not completed | 5 | 9 | 6 | 3 |
| Withdrew: Death | 1 | 3 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 3 | 0 |
| Withdrew: Sponsor decision | 1 | 4 | 0 | 2 |
| Withdrew: Withdrawal by subject | 3 | 1 | 1 | 1 |
Hematopoietic response rate is defined as the percentage of participants who had increase in hemoglobin concentration of ≥ 1 g/dL relative to baseline for 28 consecutive days during the treatment period including up to 2 months after the last dose of study treatment in the absence of red blood cell (RBC) transfusion or treatment with an erythropoiesis-stimulating agent (ESA). The percentage of participants who achieved hematopoietic response is presented.
| Percentage of Participants | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo | All Sotatercept-treated Participants |
|---|---|---|---|---|---|
| Overall | 0 (0 to 52.2) | 33.3 (7.5 to 70.1) | 50.0 (6.8 to 93.2) | 20.0 (0.5 to 71.6) | 27.8 (9.7 to 53.5) |
| Received weekly chemotherapy and showed a response | 0 (0 to 84.2) | 0 (0 to 84.2) | 25.0 (2.5 to 100.0) | 20 (2.5 to 100.0) | 5.6 (0.5 to 71.6) |
| Received less frequent chemotherapy and showed a response | 0 (0 to 70.8) | 33.3 (9.9 to 81.6) | 25.0 (0.8 to 90.6) | 0 (0 to 60.2) | 22.2 (9.1 to 61.4) |
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced AEs is reported.
| Participants | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 6 | 7 | 7 | 5 |
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study intervention due to AEs is reported.
| Participants | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Number of Participants Who Discontinued Study Intervention Due to an Adverse Event | 1 | 0 | 4 | 1 |
Percentage of participants achieving an increase from baseline hemoglobin of ≥ 2 g/dL for 28 consecutive days during the treatment period and up to 2 months after the last dose of study treatment in the absence of RBC transfusion or treatment with an ESA. The percentage of participants achieving an increase from baseline hemoglobin of ≥ 2 g/dL for 28 consecutive days is presented.
| Percentage of Participants | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo | All Sotatercept-treated Participants |
|---|---|---|---|---|---|
| Overall | 0 (0 to 52.2) | 11.1 (0.3 to 48.2) | 0 (0 to 60.2) | 0 (0 to 52.2) | 5.6 (0.1 to 27.3) |
| Received weekly chemotherapy and showed a response | 0 (0 to 84.2) | 0 (0 to 84.2) | 0 (0 to 97.5) | 0 (0 to 97.5) | 0 (0 to 52.2) |
| Received less frequent chemotherapy and showed a response | 0 (0 to 70.8) | 11.1 (0.4 to 57.9) | 0 (0 to 70.8) | 0 (0 to 60.2) | 5.6 (0.2 to 36.0) |
Percentage of participants achieving hemoglobin ≥ 11 g/dL for 28 consecutive days during the treatment period and up to 2 months after the last dose of study treatment in the absence of RBC transfusion or treatment with an ESA. The percentage of participants achieving an increase from baseline hemoglobin of ≥ 11 g/dL for 28 consecutive days is presented.
| Percentage of Participants | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo | All Sotatercept-treated Participants |
|---|---|---|---|---|---|
| Overall | 20.0 (0.5 to 71.6) | 22.2 (2.8 to 60.0) | 75.0 (19.4 to 99.4) | 20.0 (0.5 to 71.6) | 33.3 (13.3 to 59.0) |
| Received weekly chemotherapy and showed a response | 0 (0 to 84.2) | 11.1 (1.3 to 98.7) | 25.0 (2.5 to 100.0) | 20.0 (2.5 to 100.0) | 11.1 (5.3 to 85.3) |
| Received less frequent chemotherapy and showed a response | 20.0 (0.8 to 90.6) | 11.1 (0.4 to 57.9) | 50.0 (9.4 to 99.2) | 0 (0 to 60.2) | 22.2 (9.1 to 61.4) |
Percentage of participants achieving an increase from baseline hemoglobin of ≥ 2 g/dL and/or hemoglobin ≥ 11 g/dL for 28 consecutive days during the treatment period and up to 2 months after the last dose of study treatment in the absence of RBC transfusion or treatment with an ESA. The percentage of participants achieving an increase from baseline hemoglobin of ≥ 2 g/dL and/or hemoglobin ≥ 11 g/dL for 28 consecutive days is presented.
| Percentage of Participants | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo | All Sotatercept-treated Participants |
|---|---|---|---|---|---|
| Overall | 20.0 (0.5 to 71.6) | 22.2 (2.8 to 60.0) | 75.0 (19.4 to 99.4) | 20.0 (0.5 to 71.6) | 33.3 (13.3 to 59.0) |
| Received weekly chemotherapy and showed a response | 0 (0 to 84.2) | 11.1 (1.3 to 98.7) | 25.0 (2.5 to 100.0) | 20.0 (2.5 to 100.0) | 11.1 (5.3 to 85.3) |
| Received less frequent chemotherapy and showed a response | 20.0 (0.8 to 90.6) | 11.1 (0.4 to 57.9) | 50.0 (9.4 to 99.2) | 0 (0 to 60.2) | 22.2 (9.1 to 61.4) |
Duration of hematopoietic response is defined as the time period from the first time hemoglobin increases at least ≥ 1 g/dL from baseline to the last time there is hemoglobin ≥ 1 g/dL increase from baseline. Duration of response is only calculated for a responder and will be at least 28 days. The duration of response is only calculated for a patient who meets the primary efficacy endpoint. The data for duration of response for ≥ 1 g/dL from baseline is presented.
| Days | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Duration of Hematopoietic Response for Hemoglobin ≥ 1 g/dL | — | 47.0 ± 20.30 | 46.5 ± 14.85 | 29.0 ± NA |
Duration of hematopoietic response is defined as the time period from the first time hemoglobin increases at least ≥ 2 g/dL from baseline to the last time there is hemoglobin ≥ 2 g/dL increase from baseline. Duration of response is only calculated for a responder and will be at least 28 days. The duration of response is only calculated for a patient who meets the primary efficacy endpoint. The data for duration of response for hemoglobin ≥ 2 g/dL from baseline is presented.
| Days | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Duration of Hematopoietic Response for Hemoglobin ≥ 2 g/dL | — | 69.0 ± NA | — | — |
Duration of hematopoietic response is defined as the time period from the first time hemoglobin increases at least ≥ 11 g/dL from baseline to the last time there is hemoglobin ≥ 11 g/dL increase from baseline. Duration of response is only calculated for a responder and will be at least 28 days. The duration of response is only calculated for a patient who meets the primary efficacy endpoint. The data for duration of response for hemoglobin ≥ 11 g/dL from baseline is presented.
| Days | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Duration of Hematopoietic Response for Hemoglobin ≥ 11 g/dL | — | 41.0 ± NA | 50.0 ± 9.90 | 29.0 ± NA |
Duration of hematopoietic response is defined as the time period the first time hemoglobin increases ≥ 1 g/dL and/or hemoglobin concentration is ≥ 11 g/dL from baseline to the last time when the same response is maintained. The data for duration of response for hemoglobin ≥ 1 g/dL and/or hemoglobin concentration ≥ 11 g/dL from baseline is presented.
| Days | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Duration of Hematopoietic Response for Hemoglobin Increases ≥ 1 g/dL and/or Hemoglobin Concentration ≥ 11 g/dL | — | 47.0 ± 20.30 | 50.0 ± 9.90 | 29.0 ± NA |
Duration of hematopoietic response is defined as the time period the first time hemoglobin increases ≥ 2 g/dL, and/or hemoglobin concentration is ≥ 11 g/dL from baseline to the last time when the same response is maintained. The data for duration of response for hemoglobin ≥ 2 g/dL and/or hemoglobin concentration ≥ 11 g/dL from baseline is presented.
| Days | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Duration of Hematopoietic Response for Hemoglobin Increases ≥ 2 g/dL, and/or Hemoglobin Concentration ≥ 11 g/dL | — | 69.0 ± NA | 50.0 ± 9.90 | 29.0 ± NA |
Time to achieve hematopoietic response based on ≥ 1 g/dL increase from baseline, is defined as the time from first dose of study treatment to the first hemoglobin increase ≥ 1 g/dL that was maintained for at least 28 consecutive days. The data for time to achieve hematopoietic response for hemoglobin ≥ 1 g/dL from baseline is presented.
| Days | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Time to Achieve Hematopoietic Response of Hemoglobin ≥ 1 g/dL Increase From Baseline | — | NA (72.0 to NA) | NA (6.0 to NA) | NA (112 to NA) |
Time to achieve hematopoietic response based on ≥ 2 g/dL increase from baseline, is defined as the time from first dose of study treatment to the first hemoglobin increase ≥ 2 g/dL that was maintained for at least 28 consecutive days. The data for duration of response for hemoglobin ≥ 2 g/dL from baseline is presented.
| Days | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Time to Achieve Hematopoietic Response of Hemoglobin ≥ 2 g/dL Increase From Baseline | — | NA (NA to NA) | — | — |
Time to achieve hematopoietic response based on hemoglobin ≥ 11 g/dL, defined as the time from first dose of study treatment to the first hemoglobin ≥ 11 g/dL that was maintained for at least 28 consecutive days. The data for duration of response for hemoglobin ≥ 11 g/dL from baseline is presented.
| Days | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Time to Achieve Hematopoietic Response of Hemoglobin ≥ 11 g/dL From Baseline | NA (28.0 to NA) | NA (100.0 to NA) | 56.0 (6.0 to NA) | NA (112.0 to NA) |
Time to achieve hematopoietic response based on multiple criteria categories, defined as the time from first dose of study treatment to first hemoglobin increase ≥ 1 g/dL and/or hemoglobin ≥ 11 g/dL that was maintained for at least 28 consecutive days. The data for duration of response for hemoglobin increase from baseline ≥ 1 g/dL and/or ≥ 11 g/dL from baseline is presented.
| Days | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Time to Achieve Hematopoietic Response of First Hemoglobin Increase ≥ 1 g/dL and/or Hemoglobin ≥ 11 g/dL | NA (28.0 to NA) | NA (21.0 to NA) | 56.0 (6.0 to NA) | NA (112.0 to NA) |
Time to achieve hematopoietic response, defined as the time from first dose of study treatment to first hemoglobin increase ≥ 2 g/dL and/or hemoglobin ≥ 11 g/dL that was maintained for at least 28 consecutive days. The data for duration of response for hemoglobin increase from baseline ≥ 2 g/dL and/or ≥ 11 g/dL from baseline is presented.
| Days | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Time to Achieve Hematopoietic Response of First Hemoglobin Increase ≥ 2 g/dL and/or Hemoglobin ≥ 11 g/dL | NA (28.0 to NA) | NA (NA to NA) | 56.0 (6.0 to NA) | NA (112.0 to NA) |
The percentage of participants who received RBC transfusion or treatment with an ESA in each study treatment group as well as within each cycle of each study treatment is presented.
| Percentage of Participants | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Overall RBC Transfusions | 0 | 33.3 | 25.0 | 0 |
| Overall ESAs | 0 | 11.1 | 0 | 0 |
| Overall Received RBC Transfusions or ESAs | 0 | 44.4 | 25.0 | 0 |
| Day 1 to Prior to Day 29 RBC Transfusions | 0 | 11.1 | 25.0 | 0 |
| Day 1 to Prior to Day 29 ESAs | 0 | 0 | 0 | 0 |
| Day 1 to Prior to Day 29 Received RBC Transfusions or ESAs | 0 | 11.1 | 25.0 | 0 |
| Day 29 to Prior to Day 57 RBC Transfusions | 0 | 22.2 | 0 | 0 |
| Day 29 to Prior to Day 57 ESAs | 0 | 0 | 0 | 0 |
| Day 29 to Prior to Day 57 Received RBC Transfusions or ESAs | 0 | 22.2 | 0 | 0 |
| Day 57 to Prior to Day 85 RBC Transfusions | 0 | 0 | 25.0 | 0 |
| Day 57 to Prior to Day 85 ESAs | 0 | 11.1 | 0 | 0 |
| Day 57 to Prior to Day 85 Received RBC Transfusions or ESAs | 0 | 11.1 | 25.0 | 0 |
| Day 85 to Prior to Day 141 RBC Transfusions | 0 | 11.1 | 25.0 | 0 |
| Day 85 to Prior to Day 141 ESAs | 0 | 0 | 0 | 0 |
| Day 85 to Prior to Day 141 Received RBC Transfusions or ESAs | 0 | 11.1 | 25.0 | 0 |
ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR at Day 64 is presented.
| Percentage of Participants | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Complete Response | 0 | 33.3 | 0 | 0 |
| Partial Response | 0 | 16.7 | 0 | 0 |
| Stable Disease | 100.0 | 16.7 | 100.0 | 50.0 |
| Progressive Disease | 0 | 16.7 | 0 | 0 |
| Not Evaluable | 0 | 0 | 0 | 0 |
| Not Applicable | 0 | 16.7 | 0 | 50.0 |
ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR of non-target lesions at Day 64 is presented.
| Percentage of Participants | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Complete Response | 0 | 0 | 0 | 0 |
| Progressive Disease | 50.0 | 33.3 | 0 | 50.0 |
| Non-complete Response/Non-progressive disease | 50.0 | 50.0 | 100.0 | 25.0 |
| Not Evaluable | 0 | 0 | 0 | 0 |
| Not Applicable | 0 | 16.7 | 0 | 25.0 |
ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR at Day 113 is presented.
| Percentage of Participants | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Complete Response | 0 | 0 | 0 | 0 |
| Partial Response | 0 | 0 | 0 | 0 |
| Stable Disease | 100.0 | 0 | 0 | 33.3 |
| Progressive Disease | 0 | 0 | 0 | 0 |
| Not Evaluable | 0 | 0 | 0 | 0 |
| Not Applicable | 0 | 100.0 | 100.0 | 66.7 |
ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR of non-target lesions at Day 113 is presented.
| Percentage of Participants | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Complete Response | 0 | 0 | 0 | 0 |
| Progressive Disease | 0 | 0 | 100.0 | 33.3 |
| Non-complete Response/Non-progressive disease | 100.0 | 50.0 | 0 | 33.3 |
| Not Evaluable | 0 | 50.0 | 0 | 0 |
| Not Applicable | 0 | 0 | 0 | 33.3 |
PFS was defined as the time from start of the chemotherapy regimen (which could have occurred prior to study start and collected as prior anticancer therapy) to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS per RECIST 1.1 is presented.
| Days | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo | All Sotatercept-treated Participants |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) | 188.0 (64.0 to 188.0) | 196.0 (97.0 to 219.0) | 187.0 (134.0 to 1791.0) | 157.0 (84.0 to NA) | 169.0 (108.0 to 219.0) |
Collected over Up to Day 281. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sotatercept 0.1 mg/kg | 1/8 (12.5%) | 0/8 (0%) | 6/8 (75%) |
| Sotatercept 0.3 mg/kg | 3/10 (30%) | 2/10 (20%) | 7/10 (70%) |
| Sotatercept 0.5 mg/kg | 3/7 (42.9%) | 3/7 (42.9%) | 7/7 (100%) |
| Placebo | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| Total | 7/30 (23.3%) | 6/30 (20%) | 25/30 (83.3%) |
| Event | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo | Total |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/8 | 1/10 | 2/7 | 0/5 | 3/30 |
| VomitingGastrointestinal disorders | 0/8 | 1/10 | 2/7 | 0/5 | 3/30 |
| FatigueGeneral disorders | 0/8 | 0/10 | 0/7 | 1/5 | 1/30 |
| AnaemiaBlood and lymphatic system disorders | 0/8 | 0/10 | 1/7 | 0/5 | 1/30 |
| Gastric ulcer perforationGastrointestinal disorders | 0/8 | 0/10 | 1/7 | 0/5 | 1/30 |
| Peptic ulcerGastrointestinal disorders | 0/8 | 0/10 | 1/7 | 0/5 | 1/30 |
| AstheniaGeneral disorders | 0/8 | 0/10 | 1/7 | 0/5 | 1/30 |
| AnorexiaMetabolism and nutrition disorders | 0/8 | 0/10 | 1/7 | 0/5 | 1/30 |
| DehydrationMetabolism and nutrition disorders | 0/8 | 1/10 | 1/7 | 0/5 | 2/30 |
| Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/8 | 1/10 | 1/7 | 0/5 | 2/30 |
| Event | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo | Total |
|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 4/8 | 0/10 | 2/7 | 3/5 | 9/30 |
| NauseaGastrointestinal disorders | 0/8 | 1/10 | 2/7 | 3/5 | 6/30 |
| VomitingGastrointestinal disorders | 1/8 | 0/10 | 3/7 | 1/5 | 5/30 |
| LeukopeniaBlood and lymphatic system disorders | 3/8 | 0/10 | 0/7 | 2/5 | 5/30 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 1/10 | 1/7 | 2/5 | 4/30 |
| AstheniaGeneral disorders | 3/8 | 2/10 | 2/7 | 2/5 | 9/30 |
| FatigueGeneral disorders | 1/8 | 1/10 | 2/7 | 2/5 | 6/30 |
| HeadacheNervous system disorders | 1/8 | 0/10 | 2/7 | 2/5 | 5/30 |
| AnaemiaBlood and lymphatic system disorders | 1/8 | 3/10 | 2/7 | 1/5 | 7/30 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/8 | 3/10 | 1/7 | 0/5 | 4/30 |
| Age, Continuous(Years) | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 51.6 ± 9.38 | 50.8 ± 8.51 | 55.6 ± 12.53 | 49.2 ± 10.62 | 51.9 ± 9.83 |
| Sex: Female, Male(Participants) | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 8 | 10 | 7 | 5 | 30 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 8 | 10 | 7 | 4 | 29 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Weight(Kilograms) | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 67.38 ± 18.338 | 71.80 ± 9.500 | 69.94 ± 9.953 | 79.62 ± 9.926 | 71.49 ± 12.647 |
| Chemotherapy Frequency(Participants) | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Placebo | Total |
|---|---|---|---|---|---|
| Weekly | 2 | 2 | 1 | 1 | 6 |
| Less Frequently | 6 | 8 | 6 | 4 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jun 2009 to primary completion in Nov 2010, 17 months.
Results were first posted in Sep 2023, 12 years 9 months after primary completion. A results delay was requested in Nov 2017.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotatercept